Deal-Making Attitudes Begin To Shift As Funding Options Decline

Biotechnology company valuations have dropped significantly during the past year, but not yet to a level that has resulted in a lot of smaller firms selling themselves to big pharma. However, biotech companies are beginning to adjust their expectations in early deal negotiations as declining stock prices impact the number of financing options available to fund ongoing drug development programs, according to Jay Stamatis, vice president and head of business development and acquisitions at AbbVie Inc.

"It's a different time today than it was 12 months or nine months ago,” Stamatis said while speaking on a panel about pharma’s partnering “needs and wants” during Biocom’s Global...